Tajikistan GMP Certificate and Exemption from Batch Assessment: Cost Pathways for Importers

1. Key takeaways

Tajik law contains one provision of high commercial value for importers: manufacturers and importers holding a good manufacturing practice (GMP) conformity certificate are exempt from the batch-by-batch conformity assessment procedure. The wording of Article 13(4) of Law No. 1893 is that medicines and medical devices introduced into the territory or produced in the territory are exempt from the batch-by-batch conformity assessment procedure where the manufacturer and the importer hold a good manufacturing practice conformity certificate. GRZAN judges this to be the most directly valuable institutional design of the full reissue of Law No. 1893 in 2025 for import-oriented companies, because it builds a substitution relationship between a one-time investment in obtaining the GMP certificate and the recurring cost of batch-by-batch conformity assessment on every shipment.

2. Legal basis

3. Expert insights

Insight 1: the beneficiaries of the exemption are the manufacturer and the importer, listed side by side. Article 13(4) connects the two with a conjunction, which GRZAN reads as meaning that a certificate held by either the manufacturer or the importer is sufficient to trigger the exemption. This opens two distinct paths: a manufacturer may cover all of its importers in Tajikistan with its own GMP certificate, and an importer may cover the multiple products it distributes with a certificate it holds itself. Companies should model both configurations financially and choose the more economical one before committing to either route.

Insight 2: the exemption covers the batch-by-batch procedure, not conformity assessment as a whole. What is waived is the batch-by-batch procedure, while the conformity assessment regime of Article 13(1) itself remains in force. The meaning is that products holding a GMP certificate are not exempt from all assessment; they move from batch-by-batch testing to other forms of assessment. Companies should calculate the benefit as the number of batch tests avoided multiplied by the unit cost and the batch volume, not assume that all assessment costs fall to zero once the certificate is in hand.

Insight 3: Article 1(13) places good manufacturing practice inside the good pharmaceutical practices system. Good manufacturing practice is one of the six practices listed there. Combined with Article 9(7), under which the supervisory authority inspects compliance with good pharmaceutical practice requirements, the GMP certificate serves not only as the exemption voucher but also as the compliance benchmark for inspections. GRZAN notes that the system must keep operating effectively after the certificate is obtained; otherwise the company may simultaneously lose the exemption and trigger inspection risk.

Insight 4: Article 6(2)(10) lists manufacturer accreditation as one method of state regulation. The accreditation of manufacturers of medicines, medical devices and parapharmaceuticals is one of ten methods of state regulation. The provision itself does not describe the relationship between this accreditation and the GMP certificate, but both point to the confirmation of manufacturing competence. Companies can treat manufacturer accreditation and the GMP certificate as two independently attainable qualifications and evaluate the return of each in the same planning exercise.

Insight 5: the exemption interacts potentially with the classification mechanism of Article 13(5). Article 13(5) provides for classification and reclassification by degree of risk in use. If a product carries a higher risk class, the intensity and frequency of batch-by-batch assessment may rise accordingly, which makes the value of the GMP exemption greater. GRZAN recommends including the risk classification of the product as a variable when modeling the return on the exemption, since the same product can yield very different savings depending on its class.

4. Practical recommendations

1. Quantify the break-even point of the exemption against the annual batch volume. GRZAN recommends comparing the value of annual import batches multiplied by the unit cost of conformity assessment and the remaining years of certificate validity against the investment required to obtain and maintain the GMP certificate, deriving a payback period before committing to the route.
2. Compare the manufacturer path with the importer path. Under the side-by-side wording of Article 13(4), model the configuration where the manufacturer’s certificate covers all importers and the configuration where each importer’s certificate covers multiple products, and select the more economical option.
3. Maintain the system effectively after obtaining the certificate. Combined with Article 9(7), the supervisory authority inspects compliance with good pharmaceutical practice requirements. Build GMP system maintenance into the annual compliance plan to avoid simultaneously losing the exemption and triggering inspection risk.
4. Use the risk classification as a modeling variable. Under Article 13(5), the higher the product risk class, the greater the possible intensity of batch assessment and the higher the marginal benefit of the exemption; calculate the savings separately per class.
5. Evaluate manufacturer accreditation in parallel. Under Article 6(2)(10), treat manufacturer accreditation as an attainable qualification in the evaluation and compare its return horizontally with the return of the GMP certificate.

5. Verification checklist

• □ Confirmed the exemption of Article 13(4) and its beneficiaries, the manufacturer and the importer
• □ Quantified the payback period of the exemption against the annual batch volume
• □ Compared the cost of the manufacturer-held certificate path with the importer-held certificate path
• □ Confirmed that the exemption covers the batch-by-batch procedure and not conformity assessment as a whole
• □ Built GMP system maintenance into the annual compliance plan under Article 9(7)
• □ Calculated the exemption benefit separately by product risk class under Article 13(5)
• □ Evaluated the manufacturer accreditation system of Article 6(2)(10)

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a dual-track choice exists between the national route and the Union route; Uzbekistan is an observer state with only a national route; Tajikistan and Turkmenistan sit outside the Union framework and must follow purely national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries and undertakes registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com